John Byon - Imugene Senior Development

All Insiders . Australia . 
Stock . Imugene . Stakeholders . Insider . John Byon
IMU Stock   0.04  0  2.56%   

Executive

John Byon is Senior Development of Imugene
Address 4-6 Bligh Street, Sydney, NSW, Australia, 2000
Phone61 2 9423 0881
Webhttps://www.imugene.com

Imugene Management Efficiency

The company has return on total asset (ROA) of (0.5088) % which means that it has lost $0.5088 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9723) %, meaning that it generated substantial loss on money invested by shareholders. Imugene's management efficiency ratios could be used to measure how well Imugene manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Imugene's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 159 M in 2024, despite the fact that Change To Liabilities is likely to grow to (1.5 M).
Imugene has accumulated 1.55 M in total debt. Debt can assist Imugene until it has trouble settling it off, either with new capital or with free cash flow. So, Imugene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imugene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imugene to invest in growth at high rates of return. When we think about Imugene's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Maria PhillipsNine Entertainment Co
N/A
Caroline GatenbyAutosports Group
N/A
Alex ParsonsNine Entertainment Co
N/A
Lisa GreenoOhMedia
N/A
Mat YelavichoOhMedia
N/A
John OsborneCOAST ENTERTAINMENT HOLDINGS
N/A
BA FFinNine Entertainment Co
N/A
Matthew StantonNine Entertainment Co
N/A
Robbie DeryoOhMedia
N/A
Jose SacaduraCOAST ENTERTAINMENT HOLDINGS
N/A
Bill McLaughlinAiMedia Technologies
N/A
Nola HodgsonNine Entertainment Co
N/A
John PurcelloOhMedia
N/A
Tony EnacheFarm Pride Foods
N/A
Chris ToddCOAST ENTERTAINMENT HOLDINGS
N/A
Harris BaigFarm Pride Foods
N/A
Craig BremnerCapitol Health
N/A
Megan HemingwayAiMedia Technologies
N/A
Melissa JonesoOhMedia
N/A
Martin KugelerNine Entertainment Co
N/A
Donna ReidAiMedia Technologies
N/A
Imugene (IMU) is traded on Australian Securities Exchange in Australia and employs 12 people. Imugene is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-0.97
Return On Asset-0.51

Imugene Leadership Team

Elected by the shareholders, the Imugene's board of directors comprises two types of representatives: Imugene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imugene. The board's role is to monitor Imugene's management team and ensure that shareholders' interests are well served. Imugene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imugene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Leslie Chong, MD CEO
Ursula McCurry, Senior Operations
MD Woodard, Chief Officer
John Byon, Senior Development
BA ASiA, Executive Chairman
Bradley Glover, Chief Officer
Bradley MBA, Chief Officer
Giovanni Selvaggi, Chief Officer
Nathan CA, Joint Sec
PharmD MBA, Chief Officer
ACA BSc, Chief Officer
Dr BSc, Head Development

Imugene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imugene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.97
Return On Asset-0.51
Operating Margin22.86 %
Current Valuation195.99 M
Shares Outstanding7.57 B
Shares Owned By Insiders14.38 %
Shares Owned By Institutions6.60 %
Price To Book2.43 X
Price To Sales57.86 X
Revenue4.97 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Imugene Stock Analysis

When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY